Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: Case report and review of the literature

Cardiovascular Revascularization Medicine

Volumn 12, Issue 4, 2011, Pages 262-265

  Ceccarelli, Giancarlo ^a   D'Ettorre, Gabriella ^a   Mancone, Massimo ^a   Francone, Marco ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Accelerated coronary atherogenesis; Chronic inflammation; HIV; Immune activation; Percutaneous coronary intervention; Stent

Indexed keywords

ABACAVIR; ANTITHROMBOCYTIC AGENT; ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LEPTIN; LIPOPOLYSACCHARIDE; LOPINAVIR PLUS RITONAVIR; NITRATE;

ADULT; ARTICLE; ATHEROGENESIS; CASE REPORT; CHRONIC INFLAMMATION; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ELUTING STENT; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IRRITABLE COLON; MIXED INFECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; VASCULAR DISEASE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 79960708326     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2010.11.006     Document Type: Article

References (25)

1. Filardi PP, Paolillo S, Marciano C, Iorio A, Losco T, Marsico F, Scala O, Ruggiero D, Ferraro S, Chiariello M Cardiovascular effects of antiretroviral drugs: clinical review. Cardiovasc Hematol Disord Drug Targets 2008, 8:238-244.
2. Hakeem A, Bhatti S, Cilingiroglu M The spectrum of atherosclerotic coronary artery disease in HIV patients. Curr Atheroscler Rep 2010, 12:119-124.
3. Farrugia PM, Lucariello R, Coppola JT Human immunodeficiency virus and atherosclerosis. Cardiol Rev 2009, 17:211-215.
4. Martínez E, Larrousse M, Gatell JM Cardiovascular disease and HIV infection: host, virus, or drugs?. Curr Opin Infect Dis 2009, 22:28-34.
5. Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH, de Oliveira AR, Bastos Fóscolo R, de Campos Machado LJ Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010, 64:739-745.
6. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil 2010, 17:491-501. DAD study group.
7. Lai S, Bartlett J, Lai H, Moore R, Cofrancesco J, Pannu H, Tong W, Meng W, Sun H, Fishman EK Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. AIDS Patient Care STDS 2009, 23:815-824.
8. Martín-Reyes R, Galeote G, Moreno R, Sánchez-Recalde A, López De Sá E, López-Sendón JL Percutaneous coronary intervention in patients infected with human immunodeficiency virus admitted with an acute coronary syndrome: Case-control study. Med Clin (Barc) 2010.
9. Segev A, Cantor WJ, Strauss BH Outcome of percutaneous coronary intervention in HIV-infected patients. Catheter Cardiovasc Interv 2006, 68:879-881.
10. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, Daar E, Cercek B Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003, 163:457-460.
11. Boccara F, Teiger E, Cohen A, Ederhy S, Janower S, Odi G, Di Angelantonio E, Barbarini G, Barbaro G Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart 2006, 92:543-544.
12. De Lorenzo F, Collot-Teixeira S, Boffito M, Feher M, Gazzard B, McGregor JL Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures. Curr Med Chem 2008, 15:2991-2999.
13. van Leuven SI, Sankatsing RR, Vermeulen JN, Kastelein JJ, Reiss P, Stroes ES Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Curr Opin HIV AIDS 2007, 2:324-331.
14. Libby P, Okamoto Y, Rocha VZ, Folco E Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74:213-220.
15. Gonzalez VD, Landay AL, Sandberg JK Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010, 135:12-25.
16. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913-920.
17. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC, 2009 Platelet Colloquium Participants Platelet functions beyond hemostasis. J Thromb Haemost 2009, 7:1759-1766.
18. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, JM Brenchley., Douek DC Reduction of Immune Activation during Chronic HIV Infection with chloroquine therapy. J Virol 2010, 84:12082-12086.
19. Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, Weis N, Alaeus A, Sandberg JK High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus Type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009, 83:11407-11411.
20. Hognestad A, Endresen K, Wergeland R, Mellembakken JR, Mollnes TE, Omland T, Kjekshus JK, Aukrust P, Andreassen AK Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 2005, 24:1026-1032.
21. Momiyama Y, Kawaguchi A, Kajiwara I, et al. Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis 2009, 207:272-276.
22. Tsiodras S, Perelas A, Wanke C, Mantzoros CS The Hiv-1/Haart Associated Metabolic Syndrome-novel adipokines, molecular associations and therapeutic implications. J Infect 2010 Jun, 11.
23. Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, Sánchez-Margalet V Role of leptin in the activation of immune cells. Mediators Inflamm 2010, 2010:568343.
24. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008, 102:218-225.
25. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.